Makena's Accelerated Approval At Stake, Woodcock On Biobetters And Singulair's Safety Issues

Pink Sheet reporters discuss the potential withdrawal of Makena’s accelerated approval, CDER director Janet Woodcock’s remarks on the development of biobetters and the advisory committee meeting on the neuropsychiatric events safety risk for Merck’s Singulair.